Zoetis Inc. (NYSE:ZTS) had its price objective raised by Morgan Stanley from $61.00 to $70.00 in a report published on Friday. They currently have an equal weight rating on the stock.

Several other research firms have also weighed in on ZTS. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the stock a buy rating in a report on Monday, August 14th. Cowen and Company set a $70.00 target price on Zoetis and gave the stock a buy rating in a report on Monday, July 17th. Stifel Nicolaus restated a buy rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. Finally, BidaskClub lowered Zoetis from a hold rating to a sell rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $67.06.

Shares of Zoetis (ZTS) opened at $68.69 on Friday. The stock has a market capitalization of $33,471.81, a PE ratio of 31.51, a PEG ratio of 2.05 and a beta of 1.02. The company has a debt-to-equity ratio of 2.13, a quick ratio of 1.17 and a current ratio of 2.01. Zoetis has a 1-year low of $48.24 and a 1-year high of $68.80.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 66.15% and a net margin of 18.29%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. sell-side analysts anticipate that Zoetis will post 2.35 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Morgan Stanley Boosts Zoetis Inc. (ZTS) Price Target to $70.00” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/morgan-stanley-boosts-zoetis-inc-zts-price-target-to-70-00/1682104.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.61%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

Several hedge funds have recently modified their holdings of ZTS. Janus Henderson Group PLC lifted its holdings in shares of Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after buying an additional 5,734,776 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after buying an additional 3,695,449 shares during the last quarter. Waddell & Reed Financial Inc. increased its position in shares of Zoetis by 65.9% during the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock valued at $290,033,000 after purchasing an additional 2,157,803 shares during the period. BlackRock Inc. increased its position in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after purchasing an additional 1,412,829 shares during the period. Finally, AJO LP increased its position in shares of Zoetis by 4,506.8% during the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after purchasing an additional 1,243,826 shares during the period. Institutional investors own 93.04% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.